羟基脲治疗银屑病，包括HIV感染者：一项综述。
Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review.
作者信息
Lee Eric S, Heller Misha M, Kamangar Faranak, Park Kelly, Liao Wilson, Koo John
机构信息
College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
出版信息
Psoriasis Forum. 2011 Fall;17(3):180-187.
Hydroxyurea is a drug that has been long forgotten for the treatment of psoriasis. In addition to its anti-psoriatic effects, it has also been shown to have antiviral effects. This dual effect makes it a drug that dermatologists may want to consider when treating psoriasis in HIV-infected individuals. There are currently no studies that discuss the safety and efficacy of hydroxyurea in the treatment of psoriasis in this immunocompromised group; however, there are multiple reports that discuss the safety and efficacy of hydroxyurea in psoriasis and HIV separately. This review suggests that hydroxyurea is generally safe and effective. The main risk involves the hematologic adverse events (anemia, leukopenia, thrombocytopenia, and macrocytosis) which appear to be dose-dependent. Because of the common hematologic adverse events, hydroxyurea may be considered as a viable therapeutic option for patients with generalized psoriasis inadequately responsive to other safer options, whether the patient is HIV-positive or not.
羟基脲是一种长期被遗忘用于治疗银屑病的药物。除了具有抗银屑病作用外，它还被证明具有抗病毒作用。这种双重作用使得它成为皮肤科医生在治疗HIV感染个体的银屑病时可能想要考虑的一种药物。目前尚无研究讨论羟基脲在该免疫功能低下群体中治疗银屑病的安全性和有效性；然而，有多项报告分别讨论了羟基脲在银屑病和HIV治疗中的安全性和有效性。本综述表明羟基脲总体上是安全有效的。主要风险涉及血液学不良事件（贫血、白细胞减少、血小板减少和大细胞性贫血），这些似乎与剂量有关。由于常见的血液学不良事件，无论患者是否为HIV阳性，对于对其他更安全的治疗方案反应不佳的泛发性银屑病患者，羟基脲可被视为一种可行的治疗选择。
Zotero 插件